Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,016 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.
Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, Toyama T. Shimoi T, et al. Among authors: mizuno t. Breast Cancer. 2021 Jul;28(4):985-986. doi: 10.1007/s12282-021-01252-x. Breast Cancer. 2021. PMID: 33886078 Free PMC article. No abstract available.
Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, Murakami S, Yamamoto Y, Kashiwaba M, Iwata H, Uemura Y, Ohashi Y. Sawaki M, et al. Among authors: mizuno t. Jpn J Clin Oncol. 2011 May;41(5):709-12. doi: 10.1093/jjco/hyr011. Epub 2011 Feb 24. Jpn J Clin Oncol. 2011. PMID: 21355003 Clinical Trial.
Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers.
Tono Y, Ishihara M, Miyahara Y, Tamaru S, Oda H, Yamashita Y, Tawara I, Ikeda H, Shiku H, Mizuno T, Katayama N. Tono Y, et al. Among authors: mizuno t. Oncotarget. 2018 Feb 16;9(19):14909-14921. doi: 10.18632/oncotarget.24504. eCollection 2018 Mar 13. Oncotarget. 2018. PMID: 29599915 Free PMC article.
First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer.
Oda H, Ishihara M, Miyahara Y, Nakamura J, Kozuka Y, Iwasa M, Tsunoda A, Yamashita Y, Saito K, Mizuno T, Shiku H, Katayama N. Oda H, et al. Among authors: mizuno t. Case Rep Oncol. 2019 Feb 8;12(1):147-156. doi: 10.1159/000496933. eCollection 2019 Jan-Apr. Case Rep Oncol. 2019. PMID: 31043953 Free PMC article.
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study.
Mukai H, Yamaguchi T, Takahashi M, Hozumi Y, Fujisawa T, Ohsumi S, Akabane H, Nishimura R, Takashima T, Park Y, Sagara Y, Toyama T, Imoto S, Mizuno T, Yamashita S, Fujii S, Uemura Y. Mukai H, et al. Among authors: mizuno t. Br J Cancer. 2020 Jun;122(12):1747-1753. doi: 10.1038/s41416-020-0815-9. Epub 2020 Apr 2. Br J Cancer. 2020. PMID: 32238920 Free PMC article. Clinical Trial.
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.
Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, Toyama T. Shimoi T, et al. Among authors: mizuno t. Breast Cancer. 2020 May;27(3):322-331. doi: 10.1007/s12282-020-01085-0. Epub 2020 Apr 2. Breast Cancer. 2020. PMID: 32240526 Free PMC article.
3,016 results